Abstract: The invention relates to a type of novel pyridine compound and a preparation method and application thereof. Specifically, the invention relates to a compound of formula (1) and a preparation method thereof, and an application of the compound of formula (1) and pharmaceutically acceptable salts thereof as aurora kinase inhibitors in preparation of anti-tumor drugs.

Abstract: Disclosed are fused cyclic compounds as SHP2 inhibitors. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as SHP2 inhibitors. The compounds and the isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof of the present invention can be used for preparing a medicament for treating or preventing a disease related to SHP2 protein.

Abstract: Disclosed in the present invention are a class of compounds as Src inhibitors. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as Src inhibitors. The compounds and the isomers, the crystalline forms, the pharmaceutically acceptable salts, the hydrates or the solvates thereof of the present invention can be used in the preparation of a medicament for treating or preventing a disease related to Src protein.

Abstract: Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of general formula (1), and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof as MYT1 inhibitors. The compounds of the present invention as well as the isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof can be used for preparing drugs for treating or preventing diseases related to MYT1 protein.

Abstract: Disclosed in the present invention are a PARP inhibitor containing a piperazine structure, a preparation method therefor and pharmaceutical use thereof. Particularly, the present invention relates to novel compounds of general formulas (1), (2), (3), (4) and (5) and/or a pharmaceutically acceptable salt thereof, a composition comprising the compounds of general formulas (1), (2), (3), (4) and (5) and/or the pharmaceutically acceptable salt thereof, a preparation method therefor and use thereof as a PARP inhibitor in the preparation of anti-tumor drugs.

Abstract: Disclosed are a naphthyridine derivative as an ATR inhibitor, a method for preparing same, and use thereof. Specifically, the present invention relates to a naphthyridine compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an ATR inhibitor. The compound and the isomer, the crystalline form, the pharmaceutically acceptable salt, the hydrate or the solvate thereof of the present invention can be used for preparing a medicament for treating or preventing a related disease mediated by ATR protein kinase.

Abstract: Disclosed in the present invention are compounds as MYT1 inhibitors. Particularly, the present invention relates to compounds represented by general formula (1) and a preparation method therefor, as well as the use of the compounds of general formula (1), and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof as MYT1 inhibitors. The compounds of the present invention as well as the isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof can be used for preparing drugs for treating or preventing diseases related to MYT1 protein.

Abstract: The present invention relates to a 1,2,4-triazolone derivative as a DHODH inhibitor, a preparation method therefor and use thereof. Specifically, the present invention relates to a compound of general formula (1), a preparation method therefor, and use of the compound of general formula (1) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a DHODH inhibitor in the treatment of DHODH-related diseases.

Abstract: Disclosed in the present invention are a class of IDH mutant inhibitors and use thereof. In particular, the present invention relates to a class of compounds of general formula (1), a method for preparing same, and use of the compound of general formula (1) or an optical isomer, a crystalline form or a pharmaceutically acceptable salt thereof as an irreversible inhibitor of IDH mutant in the preparation of an anti-tumor drug.

Abstract: The present invention discloses a fused cyclic compound as a Wee-1 inhibitor. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in the preparation of an anti-tumor drug.

Abstract: Disclosed in the present invention are a fused cyclic compound as a Wee-1 inhibitor, a preparation method therefor and use thereof. Specifically, the present invention relates to a compound of general formula (1), a preparation method therefor, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in the preparation of an anti-tumor drug.

Abstract: The present invention discloses a pyrimidine compound as a Wee-1 inhibitor. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in preparing an anti-tumor medicament.

Abstract: The present invention provides a camptothecin derivative, a composition comprising the same and use thereof. Specifically, the present invention provides a compound of formula (1) and a preparation method therefor, and use of the compound of general formula (1) and optical isomers, crystalline forms and pharmaceutically acceptable salts thereof in the preparation of a medicament for treating cancer.

Abstract: The present invention relates to a compound of general formula (1a) or general formula (1b) and a method for preparing the same, and use of the compound of general formula (1a) or general formula (1b) and an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an irreversible inhibitor for an IDH mutant in preparing a medicament for resisting a diseases such as a tumor related to an IDH mutant protein.

Abstract: The present invention relates to a compound as represented by general formula (1), and a preparation method therefor, and the use of the compound as represented by general formula (1) and an isomer, a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as an EGFR inhibitor in the preparation of a drug against EGFR-related diseases, such as tumors.

Abstract: The present invention relates to a novel compound of general formula (1) and/or a pharmaceutically acceptable salt thereof, a composition containing the compound of general formula (1) and/or the pharmaceutically acceptable salt thereof, a method for preparing the same, and use of the same as a Wee-1 inhibitor in preparing anti-tumor drugs.

Abstract: The present invention relates to a compound of general formula (1) and a preparation method therefor and use of the compound of general formula (1) or isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as an HPK1 inhibitor. The compound of the present invention can be used for preparing a medicament for treating or preventing related diseases mediated by HPK1.

Abstract: The present invention relates to a compound of general formula (1) and a preparation method therefor, and use of the compound of formula (1) and isomers, crystalline forms and pharmaceutically acceptable salts thereof as an irreversible inhibitor for a K-Ras G12C mutant protein in preparing a medicament for resisting Ras-related diseases such as tumors.

Abstract: The present invention relates to a spiro ring-containing quinazoline compound, a preparation method therefor, and use of the compound as a K-Ras G12C inhibitor in preparing antitumor medicaments.

Abstract: The invention relates to a series of new pyrrole compounds and preparation methods and uses thereof. Specifically, the present invention relates to compounds as shown in general formula (1) and the preparation method thereof, and the uses of the compound shown in general formula (1) and optical isomers, crystal forms and pharmaceutically acceptable salts in preparation of drugs for prevention or treatment of diseases related to fungal infection.